Aarti Drugs 董事会批准了 598.5 亿卢比的 48% 溢价股票回购，收购 66.5 亿股股票。 Aarti Drugs board approved a Rs 59.85 crore 48% premium share buyback for 6.65 lakh shares.
Aarti药品委员会批准了59.85卢比的股票回购,以每股900卢比、48%的溢价购买多达6.65万卢比的股票。 Aarti Drugs board approved a Rs 59.85 crore share buyback, purchasing up to 6.65 lakh shares at Rs 900 per share, a 48% premium. 购回占公司已付资本的0.72%, 并比前一次结账价格多出59.66%的溢价。 The buyback represents 0.72% of the company's paid-up capital & has a 59.66% premium over the previous closing price. 记录日期定为9月5日。 The record date is set for 5th September. 这是Aarti药品公司自2016年以来的第六股回购,目的是提高股票价值和投资者信心。 This is Aarti Drugs' sixth share buyback since 2016, aiming to boost stock value and investor confidence. 公司在制造和销售药物辅助剂,药物中间体和特种化学品方面,报告说,与24财年第一季度相比,该公司在25财年第一季度的净利下降了30.5%,净销售额下降了16%. The company, involved in manufacturing and marketing APIs, Pharma Intermediates, and Specialty Chemicals, reported a 30.5% drop in net profit and a 16% decline in net sales in Q1 FY25 compared to Q1 FY24.